Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Nal-Irinotecan + 5-FU + Leucovorin in Advanced Biliary Tract Cancer
NCT03785873Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, nanoliposomal irinotecan in biliary tract cancer (BTC), sponsored by University of Michigan Rogel Cancer Center. Started May 2019; status: completed.
02
Drugs
nivolumabnanoliposomal irinotecan
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03785873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785873.